Hemicrania continua is not a form of migraine . It's an entirely separate primary headache disorder . The International Headache Society's International Classification of Headache Disorders, 3rd edition (ICHD-3) describes hemicrania as:
"Persistent, strictly unilateral headache, associated with ipsilateral conjunctival injection (forcing of fluid into the conjuctiva, the mucous membrane that lines the eyelids), lacrimation , nasal congestion, rhinorrhea , forehead and facial sweating, miosis , ptosis and/or eyelid edema, and/or with restlessness or agitation. The headache is absolutely sensitive to indomethacin." 2
The Research Poster
"To find safe and comparable alternative treatments for HC in patients intolerant to indomethacin." 1
"Hemicrania continua (HC) is a primary headache disorder which responds absolutely to therapeutic doses of indomethacin. Unfortunately, approximately a fourth of patients develop adverse effects leading to ...
Neuronal stabilizing agents, aka anticonvulsants or antiepileptic drugs, are among the most prescribed medications for Migraine and headache prevention. They're also used to treat some mental health disorders (bipolar disorder, depression, anxiety) as well as, of course, seizure disorders such as epilepsy. Pregabalin (Lyrica) was recently approved for the treatment of fibromyalgia. The FDA has now has analyzed reports of suicidality (suicidal behavior or ideation) from 199 placebo-controlled clinical studies of 11 of these medications: Carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR) Felbamate (Felbatol) Gabapentin (Neurontin) Lamotrigine (Lamictal) Levetiracetam (Keppra) Oxcarbazepine ( Trileptal) Pregabalin (Lyrica) Tiagabine (Gabitril) Topiramate (Topamax) Valproate (Depakote, Depakote ER, Depakene, Depacon) Zonisamide (Zonegran) The studies examined the effectiveness of the drugs in epilepsy, psychiatric disorders (e.g., bipolar disorder, depression...
The FDA has completed its analysis of reports of suicidality (suicidal behavior or ideation [thoughts]) from placebo-controlled clinical trials of neuronal stabilizing agents (anticonvulsants) used to treat epilepsy, Migraine disease, psychiatric disorders, and other conditions. Based on the outcome of this review, FDA is requiring that all manufacturers of drugs in this class include a Warning in their labeling and develop a Medication Guide to be provided to patients prescribed these drugs to inform them of the risks of suicidal thoughts or actions. In the FDA's analysis of 199 clinical trials, patients receiving neuronal stabilizing agents had approximately twice the risk of suicidal behavior or ideation (0.43%) compared to patients receiving placebo (0.22%). The increased risk of suicidal behavior and suicidal ideation was observed as early as one week after starting the neuronal stabilizing agent and continued through 24 weeks. The results were generally consisten...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.